"rationale","description","label","instanceType","name","uuid:ID","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","StudyDesign","Study Design 1","9c75cf5c-3c7e-4b0b-baae-1ca75e6d6f58","StudyDesign_1"
